Last ¥7,350 JPY
Change Today -10.00 / -0.14%
Volume 67.9K
As of 2:00 AM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

3-24-1, Takada

Toshima-ku

Tokyo, 170-8655

Japan

Phone: 81 3 3985 2020

Fax: 81 3 3985 6485

Taisho Pharmaceutical Company, Ltd. offers pharmaceuticals and health-related products, as well as health-related information and services. SEGMENTS The company operates its business in two segments: Self-medication, such as OTC products, customer goods for household and general use, and other products; Pharmaceuticals, such as Ethical drugs. Self-Medication Segment The self-medication business is one of Taisho Pharmaceutical's mainstay operations. It promotes ‘switch Rx-to-OTC’ products, incorporating active ingredients in prescription drugs into over-the-counter medicines, and opening up new fields with the creation of the Livita (derived from Life Vitality Support) brand of foods scientifically proven to be safe and useful for promoting health. Products: The company offers Self-Medication products such as the cold remedy Pabron, the gastrointestinal treatmentsTaisho Kanpo Ichoyaku, Avalon and Balancer Ichoyaku and the laxative Colac; and quality-of-life improvement products, such as the nutrient drink Lipovitan D, the hair-growth treatment RiUP, and the Livita series of ‘foods for specified health use’. Marketing: The company offers its self-medication main product line Lipovitan in approximately 19 countries, principally in Hong Kong, Taiwan, Malaysia, the Philippines, Indonesia, Thailand, Vietnam, China, Australia, the United States, and the United Kingdom. Pharmaceuticals Segment In prescription pharmaceuticals, Taisho is implementing a structure to continuously create new drugs for domestic and overseas use. In research and development, Taisho conducts in-house programs and develops tie-ups with corporations and research facilities in Japan and overseas. The company reinforced its network for gathering information from research centers in Japan, the United States and Europe to stay abreast of the latest information in pharmaceutical research. New computer-based technologies, such as genome analysis and sequence determination, screening and combinatorial chemistry, have significantly improved the quality and speed of new drug development. Taisho Toyama Pharmaceutical Co., Ltd., a sales subsidiary jointly established with Toyama Chemical Co., Ltd., is helping to expand sales channels as the company build on its efficiency in the infectious disease and anti-inflammatory fields. Products: Taisho markets approximately 20 products in Japan and approximately 90 countries worldwide, including Clarith, a macrolide antibiotic; Palux injection, a peripheral vasodilator; a nonsteroidal anti-inflammatory drug Lorcam tablets; Ancaron tablets for the treatment of cardiac arrhythmia; and an anti-ulcer agent Solon. In partnership with the medical community, Taisho works to develop market-oriented products, and through its capital and administrative tie-up with Toyama Chemical Co., Ltd., the company is striving to deliver a lineup of medications and treatments to help people in Japan and around the world richer lives by improving their health. Alliance: The company has a business alliance with Toyama Chemical Co., Ltd., Taisho established a new joint venture Taisho Toyama Pharmaceutical Co., Ltd., specialized in sales and marketing of prescription drugs in Japan. Markets: The company’s major pharmaceutical product line Clarith is marketed throughout Abbott Laboratories of the U.S. to approximately 90 countries. The company also operates in Asia markets, Europe and United Kingdom markets. Significant Events Bayer Schering Pharma AG has entered into a license and option agreement with Taisho Pharmaceutical Co., Ltd., Nihon Nohyaku Co. Ltd., and the National Institute of Radiological Sciences (NIRS), Japan, to develop imaging compounds for the detection of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and other disorders also associated with neuroinflammation such as multiple sclerosis. Chugai Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd. would co-develop and market antiresorptive bisphosphonate R484, (generic name: ibandronic acid) for treatment of osteoporosis in post-menopausal women. R484 is in phase II clinical trials in Japan. It is marketed under the brand name Bonviva in the U.S. Pfizer, Inc. has signed a collaboration deal with Taisho Pharmaceutical Co. Ltd. to research, develop and commercialize TS-032, a new schizophrenia drug candidate discovered by Taisho and in pre-clinical development. Taisho would grant development and commercialization rights outside Japan for TS-032 to Pfizer. Roche's Japanese subsidiary, Chugai has entered into an agreement with Taisho Pharmaceutical Co., Ltd. to co-develop and co-market ED-71 (eldecalcitol), an activated vitamin D derivative that Chugai is developing in Japan for the treatment of osteoporosis. History Taisho Pharmaceutical Company, Ltd. was founded in 1912.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4581:JP ¥7,350.00 JPY -10.00

4581 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4581.
View Industry Companies
 

Industry Analysis

4581

Industry Average

Valuation 4581 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAISHO PHARMACEUTICAL HOLDIN, please visit www.taisho-holdings.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.